Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Needlestick prevention footage from German industry:

This article was originally published in Clinica

Executive Summary

A seven-minute film on measures taken in the operating room and wards to avoid needlestick injuries has been uploaded onto the website of German industry association BVMed, and can be viewed at: http://tvservice.bvmed.de/tvangebot.php. Some 4.2 million staff are employed in the German health system, as well as countless cleaning staff, all of whom may be reasonably assumed to be exposed to the risk of needlesticks and consequent transfer of bloodborne disease. Industry estimates that here are half a million accidental needlesticks in Germany every year. The "Safety First Initiative" says that HBV is transferred in three out of every 1,000 sticks, AIDS in 3/1,000 and HCV in 30/1,000. Modern medtech products incorporating safety features can cut these risk levels.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel